Proud moment for Magellan Biologics & Consulting !
Following the recent publication in Antibodies – based on Pfizer’s outstanding experimental work and co-authored with Magellan Biologics and ExcellGene “A Robust, High-Titer, Semi-Automated, and In-Culture Antibody-Capturing Transient CHO Platform Technology” we’re truly delighted to share that Magellan Biologics has been recognized as the TOP Transient Protein Expression in Mammalian Cells company in Europe for 2025 by Life Science Review Europe!
This award celebrates our continuous commitment to innovation in transient gene expression – and the impact of our CHO 4Tx® platform, enabling robust, high-yield protein production even for the most challenging molecules.
New Peer-Reviewed Paper in Antibodies Highlights Pfizer’s Outstanding Results with CHO 4Tx®
At the heart of this publication, entitled “A Robust, High-Titer, Semi-Automated, and In-Culture Antibody-Capturing Transient CHO Platform Technology” and co-authored by Pfizer, Magellan Biologics, and
7 November 2025
